Researchers conducted a retrospective cross-sectional analysis of patients diagnosed with de novo metastatic breast cancer to evaluate presentation and treatment differences across three main subtypes ...
MedPage Today on MSN
Novel drug impresses in metastatic pancreatic cancer
"We need to focus on getting these drugs to patients quickly," expert says ...
Daraxonrasib delivered a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy in previously ...
Wonderful Children, a great career which I enjoyed beyond words and a lovely life with my husband,” she wrote Brianne ...
Before my daughter was diagnosed with breast cancer, the “M” word was not a part of my vocabulary.
An investigational targeted therapy doubled survival compared with standard chemotherapy for pretreated individuals with ...
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer ...
Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 303, ...
A French study found that among patients under 40 with early-onset colorectal cancer, multiple-site metastases increased by 10% annually from 2004 to 2021, with no survival improvement for those with ...
First-time seizures were associated with a higher risk of neurologic and non-neurologic cancers within 1 year and beyond, a ...
Breast cancer can go away for a while and then show up again. It can also spread to different areas of your body when it comes back. Sometimes, breast cancer returns and spreads to the pleura, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results